Who
Joanne M. Donovan
Cmo
Company insider
Files Form 4 as: Cmo, Edgewise Therapeutics; CMO; SVP Clinical Development, Catabasis Pharmaceuticals.
In numbers
- Trades disclosed
- 83
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $10.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 30 Jun 2015
- Last trade
- 13 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $127K2,919 at $43.41 | filing |
| 13 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $127K2,919 at $43.41 | filing |
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —7,031 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $124K2,839 at $43.78 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,031 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $121K2,779 at $43.71 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,620104 at $44.43 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K800 at $44.52 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,031 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —7,031 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.